NCT01660815已完成1 期
PET Whole Body Biodistribution Using Florbetapir (18F)
Avid Radiopharmaceuticals1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Whole Body Radiation Dosimetry
研究概览
简要总结
This study will determine how florbetapir (18F) (18F-AV-45) radioactivity is distributed throughout the body of Japanese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are Japanese cognitively normal healthy males or females at least 45 years of age;
- •Give informed consent; and
- •Are able to lie still on the imaging table for periods up to one hour.
排除标准
- •Have had radiation exposure (PET, SPECT or CT scans) for experimental purposes within the last year;
- •Are claustrophobic or otherwise unable to tolerate the imaging procedure;
- •Have medical conditions or surgical history that would confound evaluation of dosimetry (e.g., liver disease, colectomy etc.);
- •Have current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:
- •cardiac surgery or myocardial infarction within the last 6 months;
- •unstable angina;
- •coronary artery disease that required a change in medication within the last 3 months;
- •decompensated congestive heart failure;
- •significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status;
- •severe mitral or aortic valvular disease;
- •uncontrolled high blood pressure;
- •congenital heart disease;
- •clinically significant abnormal result on ECG, including but not limited to QTc>450 msec; Before enrolling a patient with any evidence of the above conditions, the investigator must contact the sponsor;
- •Have current clinically significant medical comorbidities, as indicated by history, physical exam, or laboratory evaluations that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication or limit interpretation of the trial results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer;
- •Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse;
- •Have a history of epilepsy or convulsions, except for febrile convulsions during childhood;
- •Have clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2;
- •Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session;
- •Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Females of childbearing potential must not be pregnant (negative serum β-HCG at the time of screening) or breastfeeding at screening. Females must agree to avoid becoming pregnant, and must agree to refrain from sexual activity or to use reliable methods of contraception such as prescribed birth control or IUD for 24 hours following administration of florbetapir (18F);
- •Have a history of severe drug allergy or hypersensitivity;
- •Received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication in the last 30 days.
- •Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication;
- •Have known hypersensitivity to alcohol; and
- •In the opinion of the investigator, are otherwise unsuitable for a study of this type.
研究组 & 干预措施
Healthy Volunteers
Experimental
Cognitively normal, healthy volunteers at least 45 years of age.
干预措施: florbetapir (18F) (Drug)
结局指标
主要结局
Whole Body Radiation Dosimetry
时间窗: 0-360 minutes
Radiation dose values (millisieverts/megabecquerel \[mSv/MBq\]) were calculated for target organs, including the adrenals, brain, breasts, gall bladder wall, heart wall, kidneys, lower large intestine wall, liver, lungs, muscle, ovaries, osteogenic cells, pancreas, red marrow, skin, small intestine, spleen, stomach wall, testes, thymus, thyroid, total body, upper large intestine wall, urinary bladder wall, and uterus.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of 18F-AV-45 in Healthy VolunteersAlzheimer DiseaseNCT01564706Avid Radiopharmaceuticals9
未知
1 期
PET Whole Body Biodistribution Using Florbetapir (18F)Japanese Healthy VolunteersJPRN-jRCT2080221887Eli Lilly Japan K.K.
已完成
1 期
Use of [18F]FECNT in Positron Emission TomographyHealthyNCT00083629National Institute of Mental Health (NIMH)30
已完成
早期 1 期
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory DiseasesAutoimmune DiseaseInflammatory DisorderRheumatoid ArthritisSystemic Lupus ErythematosusCrohn DiseaseTakayasu ArteritisNCT02925351Jonsson Comprehensive Cancer Center8
已完成
不适用
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory DiseasesInflammationCancerNCT01180907Jonsson Comprehensive Cancer Center10